Candel Therapeutics, Inc.
CADLNASDAQHealthcare● Active
$8.50
$-0.01(-0.12%)
Market Cap$466657506
P/E Ratio—
52W High$9.27
52W Low$4.35
Candel Therapeutics, Inc. (CADL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CADL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.14
Est. -$0.22 · +36.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CADL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.22 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.22 | -$0.14 | +36.4% | — | — | — |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.24 | -$0.54 | -125.0% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.17 | -$0.21 | -23.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.17 | -$0.09 | +47.1% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.24 | $0.13 | +154.2% | — | — | — |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$0.23 | -$0.40 | -73.9% | — | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$0.33 | — | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.22
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$0.22
EPS Surpr.
+36.4%
Revenue
—
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.54
EPS Est.
-$0.24
EPS Surpr.
-125.0%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.21
EPS Est.
-$0.17
EPS Surpr.
-23.5%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.17
EPS Surpr.
+47.1%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
$0.13
EPS Est.
-$0.24
EPS Surpr.
+154.2%
Revenue
—
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$0.40
EPS Est.
-$0.23
EPS Surpr.
-73.9%
Revenue
—
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.33
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q4 FY2026 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Q3 FY2026 | $-0.26 | $-0.26 | $-0.25 | 1 |
| Q2 FY2026 | $-0.28 | $-0.24 | $-0.17 | 2 |
| Q1 FY2026 | $-0.35 | $-0.30 | $-0.23 | 3 |
| Q4 FY2025 | $-0.25 | $-0.24 | $-0.22 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +36.4% | $8.94 | $8.91 | -0.34% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -125.0% | $5.10 | $4.98 | -2.35% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -23.5% | $4.92 | $4.61 | -6.30% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +47.1% | $6.40 | $6.04 | -5.63% |
| ▲ Q2 FY2025 | May 13, 2025 | +154.2% | $5.01 | $5.40 | +7.78% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -73.9% | $8.09 | $7.94 | -1.85% |
| — Q4 FY2024 | Nov 14, 2024 | — | $4.29 | $4.30 | +0.23% |
| — Q3 FY2024 | Aug 13, 2024 | — | $5.58 | $5.84 | +4.66% |
Q2 FY2026-0.34%
Report Date
May 14, 2026
EPS Beat/Miss
+36.4%
Price Before
$8.94
Price After
$8.91
Q1 FY2026-2.35%
Report Date
Mar 12, 2026
EPS Beat/Miss
-125.0%
Price Before
$5.10
Price After
$4.98
Q4 FY2025-6.30%
Report Date
Nov 13, 2025
EPS Beat/Miss
-23.5%
Price Before
$4.92
Price After
$4.61
Q3 FY2025-5.63%
Report Date
Aug 14, 2025
EPS Beat/Miss
+47.1%
Price Before
$6.40
Price After
$6.04
Q2 FY2025+7.78%
Report Date
May 13, 2025
EPS Beat/Miss
+154.2%
Price Before
$5.01
Price After
$5.40
Q1 FY2025-1.85%
Report Date
Mar 13, 2025
EPS Beat/Miss
-73.9%
Price Before
$8.09
Price After
$7.94
Q4 FY2024+0.23%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$4.29
Price After
$4.30
Q3 FY2024+4.66%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$5.58
Price After
$5.84
Avg Beat Reaction+0.60%
Avg Miss Reaction-3.50%
Beat Rate3 / 8 quarters
Largest Move+7.78% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CADL ends December
Candel Therapeutics, Inc. (CADL) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.14 — beating the analyst consensus of $-0.22 by +36.4%. The next CADL earnings date is expected around September 1, 2026.
Each quarter, investors track CADL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CADL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CADL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CADL earnings · 5 questionsCandel Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CADL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CADL historically reports after market close (AMC).
CADL earnings datewhen is CADL earningsCADL next earnings datewhen does CADL report earningsCADL earnings calendar
▸ Source: FMP · Candel Therapeutics, Inc. SEC filings · US GAAP · Candel Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026